Media Advisory: New Amitiza (lubiprostone) and Irritable Bowel Syndrome with Constipation Data Presented at th New data on the efficacy of AMITIZA 8 mcg, twice daily, and impact of irritable bowel syndrome with constipation (IBS-C) on employment and cost figures will be presented in poster format at the American College of Gastroenterology 2008...
MEDIA ADVISORY: New AMITIZA(R) (lubiprostone) and Irritable Bowel Syndrome with Constipation Data Presented at New data on the efficacy of AMITIZA 8 mcg, twice daily, and impact of irritable bowel syndrome with constipation (IBS-C) on employment and cost figures will be presented in poster format at the American College of Gastroenterology 2008...
Sucampo Pharmaceuticals Announces Positive Results from a Japanese Phase 2b Dose-Ranging Study of AMITIZA for - (NewsRx.com) -- (NASDAQ: SCMP) announced results of its phase 2b dose-ranging study of AMITIZA(R) (lubiprostone) in patients with Chronic Idiopathic Constipation (CIC), conducted in Japan.The study demonstrated a statistically...
Sucampo Pharmaceuticals Announces Positive Results from a Japanese Phase 2b Dose-Ranging Study of AMITIZA for - (NewsRx.com) -- (NASDAQ: SCMP) announced results of its phase 2b dose-ranging study of AMITIZA(R) (lubiprostone) in patients with Chronic Idiopathic Constipation (CIC), conducted in Japan.The study demonstrated a statistically...
Sucampo Pharmaceuticals Announces Positive Results from a Japanese Phase 2b Dose-Ranging Study of AMITIZA for _ Sucampo Pharmaceuticals Announces Positive Results from a Japanese Phase 2b Dose-Ranging Study of AMITIZA for.
Sucampo Pharmaceuticals Invites Investors to Listen to Webcast of Presentation at UBS Conference - Sucampo Pharmaceuticals, Inc.(NASDAQ:SCMP) today announced that its presentation at the UBS Global Life Sciences Conference will be webcast and may be accessed at www.sucampo.com A member of Sucampo Pharmaceuticals Investors interested...
Sucampo announces positive phase 2b study of Amitiza Sucampo Pharmaceuticals, Inc announced results of its phase-2b dose-ranging study of Amitiza (lubiprostone) in patients with Chronic Idiopathic Constipation (CIC), conducted in Japan.The study demonstrated a statistically...
Sucampo Pharmaceuticals Invites Investors to Listen to Webcast of Presentation at UBS Conference A member of Sucampo Pharmaceuticals Investors interested in listening to the live webcast should log on before the start time in order to download any software required.The archive of the webcast will be available for several days after...
Sucampo Pharmaceuticals Invites Investors to Listen to Webcast of Presentation at UBS Conference BETHESDA, MD--(BUSINESS WIRE)--Sucampo Pharmaceuticals, Inc.(NASDAQ:SCMP - News) today announced that its presentation at the UBS Global Life Sciences Conference will be webcast and may be accessed at www.sucampo.com A member of Sucampo...
Sucampo Pharmaceuticals Invites Investors to Listen to Webcast of Presentation at UBS Conference BETHESDA, MD - (Business Wire) Sucampo Pharmaceuticals, Inc.(NASDAQ:SCMP) today announced that its presentation at the UBS Global Life Sciences Conference will be webcast and may be accessed at www.sucampo.com A member of Sucampo...
Sucampo Pharmaceuticals Invites Investors to Listen to Webcast of Presentation at UBS Conference BETHESDA, MD -- (Business Wire) Sucampo Pharmaceuticals, Inc.(NASDAQ:SCMP) today announced that its presentation at the UBS Global Life Sciences Conference will be webcast and may be accessed at www.sucampo.com A member of Sucampo...
Sucampo Pharmaceuticals Invites Investors to Listen to Webcast of Presentation at UBS Conference Sucampo Pharmaceuticals, (News) Inc.(NASDAQ:SCMP) today announced that its presentation at the UBS Global Life Sciences Conference will be webcast and may be accessed at www.sucampo.com A member of Sucampo Pharmaceuticals' Investors...
22 Sep 08 | Sucampo reports positive results from Phase IIb constipation trial results from Phase IIb constipation trial Sucampo Pharmaceuticals, a biopharmaceutical company, has announced positive results of its Phase IIb dose-ranging study of Amitiza in patients with chronic idiopathic constipation conducted in...
Sucampo Pharmaceuticals Announces Positive Results from a Japanese Phase 2b Dose-Ranging Study of AMITIZA for BETHESDA, MD--(BUSINESS WIRE)--Sept.18, 2008 - Sucampo Pharmaceuticals, Inc.
(NASDAQ: SCMP) today announced results of its phase 2b dose-ranging study of AMITIZA(R) (lubiprostone) in patients with Chronic Idiopathic Constipation (CIC),...
Sucampo reports positive results from Phase IIb constipation trial The study has demonstrated a statistically significant increase in mean change in spontaneous bowel movements (SBM) from baseline after one week on treatment (p<0.0001), the study's primary endpoint, for patients taking Amitiza 24...
Sucampo Pharmaceuticals Announces Positive Results from a Japanese Phase 2b Dose-Ranging Study of AMITIZA(R) f Sucampo Pharmaceuticals, Inc.(NASDAQ: SCMP) today announced results of its phase 2b dose-ranging study of AMITIZA(R) (lubiprostone) in patients with Chronic Idiopathic Constipation (CIC), conducted in Japan.
The study demonstrated a...
Sucampo Pharmaceuticals Announces Positive Results from a Japanese Phase 2b Dose-Ranging Study of AMITIZA(R) f BETHESDA, MD--(BUSINESS WIRE)--Sucampo Pharmaceuticals, Inc.(NASDAQ: SCMP - News) today announced results of its phase 2b dose-ranging study of AMITIZA (lubiprostone) in patients with Chronic Idiopathic Constipation (CIC), conducted...
Sucampo Pharmaceuticals Announces Positive Results from a Japanese Phase 2b Dose-Ranging Study of AMITIZA(R) f - Sucampo Pharmaceuticals, Inc.(NASDAQ: SCMP) today announced results of its phase 2b dose-ranging study of AMITIZA AMITIZA 24 mcg also demonstrated statistically significant improvement versus placebo for several secondary...
Sucampo Pharmaceuticals Announces Positive Results from a Japanese Phase 2b Dose-Ranging Study of AMITIZA(R) f Sucampo Pharmaceuticals, (News) Inc.(NASDAQ: SCMP) today announced results of its phase 2b dose-ranging study of AMITIZA AMITIZA 24 mcg also demonstrated statistically significant improvement versus placebo for several...
Sucampo Pharmaceuticals Announces Positive Results from a Japanese Phase 2b Dose-Ranging Study of AMITIZA(R) f BETHESDA, MD--(BUSINESS WIRE)--Sept.18, 2008 - Sucampo Pharmaceuticals, Inc.
(NASDAQ: SCMP) today announced results of its phase 2b dose-ranging study of AMITIZA(R) (lubiprostone) in patients with Chronic Idiopathic Constipation (CIC),...
Sucampo Pharmaceuticals Announces Positive Results from a Japanese Phase 2b Dose-Ranging Study of AMITIZA(R) f - Sucampo Pharmaceuticals, Inc.Kate de Santis, 240-223-3834 or Westwicke Partners, LLC John Woolford, 410-321-9653 John.Woolford@westwickepartners.com Sucampo Pharmaceuticals, Inc.
(NASDAQ: SCMP) today announced results of its phase 2b...
Sucampo Pharmaceuticals Announces Positive Results from a Japanese Phase 2b Dose-Ranging Study of AMITIZA(R) f BETHESDA, MD--(BUSINESS WIRE)-- Sucampo Pharmaceuticals, Inc.(NASDAQ: SCMP) today announced results of its phase 2b dose-ranging study of AMITIZA(R) (lubiprostone) in patients with Chronic Idiopathic Constipation (CIC), conducted in Japan...
GlowWorm Builds Executive Ranks AGENCY SEES GROWTH IN CONSUMER HEALTH MARKETING NEW YORK, Sept.18, 2008 Seeing opportunities in the fast changing consumer healthcare marketing arena, Glow Worm announced that it has hired Mark Drossman as EVP, Executive Creative Director...
Sucampo names new board member Dr Dolecek is currently Sucampo's senior vice president of R&D.Dr Dolecek has received his BS from the University of Maryland and a MPH in health services and planning from the University of Hawaii.
Ryuji Ueno, chairman and CEO of...
Sucampo Pharmaceuticals Strengthens Its Board of Directors BETHESDA, MD--(BUSINESS WIRE)--Sucampo Pharmaceuticals, Inc.(NASDAQ:SCMP - News) today announced that Gayle Dolecek, P.D., M.P.H., has been appointed to its Board of Directors.
Dolecek is currently Sucampos Senior Vice President of...
